BACKGROUND: High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone. METHODS: ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays constructed from 123 patients with stages I-II laryngeal squamous cell carcinoma treated with standard radiotherapy. RESULTS: ERCC1 expression did not correlate with clinicopathologic risk factors, local control, or overall survival. At 5 years, local control was 75% versus 71% (p = .78) and overall survival was 68% versus 54% (p = .65), for nonexpressors and expressors of ERCC1, respectively. On multivariate analysis, T classification predicted for local control, and T classification and age predicted for overall survival. CONCLUSIONS: ERCC1 expression did not predict for radiotherapy resistance or worse survival. Therefore, radiotherapy remains an effective treatment in tumors with high ERCC1 expression.
BACKGROUND: High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone. METHODS:ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays constructed from 123 patients with stages I-II laryngeal squamous cell carcinoma treated with standard radiotherapy. RESULTS:ERCC1 expression did not correlate with clinicopathologic risk factors, local control, or overall survival. At 5 years, local control was 75% versus 71% (p = .78) and overall survival was 68% versus 54% (p = .65), for nonexpressors and expressors of ERCC1, respectively. On multivariate analysis, T classification predicted for local control, and T classification and age predicted for overall survival. CONCLUSIONS:ERCC1 expression did not predict for radiotherapy resistance or worse survival. Therefore, radiotherapy remains an effective treatment in tumors with high ERCC1 expression.
Authors: Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz Journal: J Clin Oncol Date: 2001-12-01 Impact factor: 44.544
Authors: P Ceppi; M Volante; S Novello; I Rapa; K D Danenberg; P V Danenberg; A Cambieri; G Selvaggi; S Saviozzi; R Calogero; M Papotti; G V Scagliotti Journal: Ann Oncol Date: 2006-09-15 Impact factor: 32.976
Authors: R Metzger; C G Leichman; K D Danenberg; P V Danenberg; H J Lenz; K Hayashi; S Groshen; D Salonga; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; B Konda; L Leichman Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Corinne M Doll; Michael Prystajecky; Misha Eliasziw; Alexander C Klimowicz; Stephanie K Petrillo; Peter S Craighead; Desiree Hao; Roman Diaz; Susan P Lees-Miller; Anthony M Magliocco Journal: Radiother Oncol Date: 2010-10-09 Impact factor: 6.280
Authors: Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley Journal: Exp Cell Res Date: 2019-05-07 Impact factor: 3.905